Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever (with M. Mendenhall, A. Russell, Donald F. Smee, Jeffery O. Hall, Ramona T. Skirpstunas, and Y. Furuta), PLoS Neglected Tropical Diseases (2011)

Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir (with K. K. Buys, K. H. Jung, D. F. Smee, and Y. Furuta), Antiviral Chemistry & Chemotherapy (2011)

Progress in the experimental therapy of severe arenaviral infections (with M. Bray), Future Microbiology (2011)

T-705 (Favipiravir) inhibition of arenavirus replication in cell culture (with M. Mendenhall, A. Russell, T. Juelich, E. L. Messina, D. F. Smee, A. N. Freiberg, M. R. Holbrook, Y. Furuta, J. C. de la Torre, and J. H. Nunberg), Antimicrobial Agents and Chemotherapy (2011)

Use of recombinant adenovirus vectored 1 consensus IFN-α to avert severe arenavirus infection (with J. Ennis, A. Russell, E. J. Sefing, M. H. Wong, and J. Turner), PLoS ONE (2011)

View More »